Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells for Drug Discovery & Toxicity Screening 2017

Mark Bradley's Biography



Mark Bradley, Professor of Therapeutic Innovation, Precision Healthcare University Research Institute, Queen Mary University of London

Mark received his doctorate from the University of Oxford in 1989, followed by post-doctoral studies at Harvard and returning to the UK as a Royal Society University Research Fellow (University of Southampton). In 1997 he was made a Professor of Combinatorial Chemistry setting up the UK’s Centre for Combinatorial Chemistry. In 2005 he moved to the University of Edinburgh, where he was Director of a £15M Interdisciplinary Research Collaboration in the area of Optical Molecular Imaging (Proteus 2014-2023) and a Doctorial Training Centre (60PhD) in Optical Imaging with Entrepreneurship. In Aug 2023 he moved to Queen Mary University of London as Professor of Therapeutic Innovation and part of the Precision Healthcare university Research Institute. He held an ERC Advanced Grant on “SmartMaterials” for cellular control. He is a co-founder of Ilika Technologies (2004) (which floated on AIMS in 2010), DestiNA Technologies (2010) and Edinburgh Molecular Imaging (2014) and Biocaptiva (2021).

Mark Bradley Image

Substrates for Generating Cancer Stem Cells and Highly Functional Hepatocytes

Tuesday, 11 July 2017 at 13:30

Add to Calendar ▼2017-07-11 13:30:002017-07-11 14:30:00Europe/LondonSubstrates for Generating Cancer Stem Cells and Highly Functional HepatocytesStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

In my talk I will introduce polymer microarray technology; including our inkjet mediated fabrication methodologies (which allows over 7000 different substrates to be made on a single glass slide) and describe how this approach has been used in a large number of stem cell based applications, notably:

(i). The use of polymer microarray technology to discover a novel thermo-responsive chemically-defined hydrogel for long term culture of human embryonic stem cells (Nature Communication, 2013) and mesenchymal adipose derived stem cells (Biomaterials, 2014)

(ii). Polymer discovery that were able to support highly functional hESC-derived hepatocyte like cells (as active as primary human hepatoctyes) (with David Hay see: Stem Cell Res, 2011 and WO2010106345)

(iii). The discovery and application of a substrate able to “lock-down” CSC’s in their CSC state


Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com